Category: General

Ann Vasc Surg. 2025 Jan;110(Pt A):498-504. doi: 10.1016/j.avsg.2024.08.032. Epub 2024 Oct 17.

ABSTRACT

BACKGROUND: The treatment outcomes of vein and bovine pericardial patches in thromboendarterectomy (TEA) for common femoral artery (CFA) lesions in patients with peripheral arterial disease (PAD) remain unclear. The purpose of this study was to evaluate the efficacy and safety of the bovine pericardial patch by comparing it with vein patch angioplasty.

METHODS: This was a multicenter retrospective study. We reviewed the data of patients who underwent TEA with patch angioplasty (vein versus bovine pericardial patch angioplasty) for PAD between January 2018 and December 2022. Indication for revascularization is patients with PAD with claudication symptoms to rest pain and foot ulcers that interfere with daily life, with lesions in the CFA region. The primary end point was 2-year patency. The secondary end points were postoperative wound complications, including patch rupture, and safety of remote-phase puncture of the patch area after patch angioplasty.

RESULTS: Within the observation period, TEA was performed on 157 limbs in 136 patients using vein patches and on 86 limbs in 79 patients using bovine pericardial patches. The number of claudication/rest pain/tissue loss was 110/13/34 cases in the vein patch group and 57/14/15 cases in the bovine pericardial patch group, respectively. No significant differences were observed in patient characteristics. No significant between group differences were observed in operative time, blood loss, or percentage of patients who underwent concomitant revascularization during the procedure. The 2-year primary patency rates of the vein and bovine pericardial patch were 95.6% and 92.8%, respectively (P = 0.49). The rate of surgical site infection in this study was 2.5% in the vein patch group and 5.8% in the bovine pericardial patch group, respectively (P = 0.29). Rupture of the patch occurred in 4 (2.5%) and 4 (4.7%) patients in the vein and bovine pericardial patch groups, respectively (P = 0.46), and the percentage of cases requiring revision of the patch site was 7 (4.5%) and 5 (5.8%) in the vein and bovine pericardial patch groups, respectively (P = 0.76). Postoperatively, 23 patients in the vein and 13 patients in the bovine pericardial patch groups underwent patch puncture during the remote period. The median follow-up duration from the date of the surgery to the date of the puncture was 544 days and 374 days in the vein and bovine pericardial patch groups, respectively. No patch-related complications were observed during remote stage puncture.

CONCLUSIONS: Compared with vein patches, TEA with bovine pericardial patches had acceptable outcomes in terms of patency and postoperative complications.

PMID:39424177 | DOI:10.1016/j.avsg.2024.08.032

Indian J Thorac Cardiovasc Surg. 2025 Jan;41(1):35-40. doi: 10.1007/s12055-024-01769-8. Epub 2024 Jul 1.

ABSTRACT

AIM: To evaluate the short-term outcomes of Tissue Engineered Decellularized Bovine pericardium (Synkroscaff®) in congenital heart surgery as a prosthetic material.

METHODOLOGY: This is a prospective observational cohort study. SynkroScaff® was used as prosthetic material in cohort of successive patients under 18 years of age requiring cardiac surgery for congenital heart diseases. Patients were evaluated for residual shunt, infective endocarditis, stenosis, calcification and aneurysmal dilatation at discharge, after 1 month, 3 months, 6 months and 1 year post-operatively.

RESULTS: Ninety-two patients were included, and the patch was used in ventricular septal defect (VSD), closure, aortic arch reconstructions and pulmonary arterioplasty (tetralogy of Fallot repair). Four (4.3%) had transient heart block, one had complete heart block needing a permanent pacemaker. A residual shunt was present in less than 5% of the VSD patients which spontaneously closed within 12 months. One patient of VSD repair had a significant residual shunt requiring redo surgery. The intra-operative ease of handling was rated as 9/9 in 92.3% of patients. None of the patients were noticed to develop patch leaks, aneurysmal dilatation or calcification on 12-month follow-up.

CONCLUSIONS: This tissue engineered bovine pericardium is a safe and reliable prosthetic material for corrective congenital heart surgery in short-term period.

PMID:39679085 | PMC:PMC11638438 | DOI:10.1007/s12055-024-01769-8